Patents by Inventor Ihab Darwish
Ihab Darwish has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250092057Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: ApplicationFiled: September 27, 2024Publication date: March 20, 2025Inventors: Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
-
Patent number: 12227508Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.Type: GrantFiled: October 7, 2022Date of Patent: February 18, 2025Assignee: Rigel Pharmaceuticals, Inc.Inventors: Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
-
Publication number: 20240368119Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: ApplicationFiled: March 29, 2024Publication date: November 7, 2024Inventors: Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
-
Patent number: 12043629Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: GrantFiled: January 13, 2023Date of Patent: July 23, 2024Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ihab Darwish, Zhushou Luo, Vanessa Taylor
-
Publication number: 20240217958Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: ApplicationFiled: February 5, 2024Publication date: July 4, 2024Inventors: Vanessa TAYLOR, Jiaxin YU, Esteban MASUDA, Ihab DARWISH, Yan CHEN
-
Patent number: 11919890Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: GrantFiled: March 23, 2021Date of Patent: March 5, 2024Assignee: ;Eli Lilly and CompanyInventors: Vanessa Taylor, Jiaxin Yu, Esteban Masuda, Ihab Darwish, Yan Chen
-
Publication number: 20230310454Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: ApplicationFiled: December 6, 2022Publication date: October 5, 2023Inventors: Jiaxin YU, Ihab DARWISH, Vanessa TAYLOR, Rao KOLLURI, Yan CHEN, Simon SHAW, Somasekhar BHAMIDIPATI, Zhushou LUO
-
Publication number: 20230312568Abstract: Disclosed embodiments concern compounds according to Formula I In some embodiments, the compounds are useful as kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are compositions comprising such inhibitors, and methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.Type: ApplicationFiled: March 30, 2023Publication date: October 5, 2023Applicant: Rigel Pharmaceuticals, Inc.Inventors: Zhushou Luo, Simon Shaw, Ihab Darwish, Estaban Masuda, Chrystelle Lamagna
-
Publication number: 20230265100Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: ApplicationFiled: April 26, 2023Publication date: August 24, 2023Inventors: Somasekhar BHAMIDIPATI, Simon SHAW, Ihab DARWISH, Jiaxin YU, Rao KOLLURI, Vanessa TAYLOR, Esteban MASUDA, Mark IRVING
-
Publication number: 20230227469Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: ApplicationFiled: January 13, 2023Publication date: July 20, 2023Inventors: Ihab DARWISH, Zhushou LUO, Vanessa TAYLOR
-
Patent number: 11672791Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.Type: GrantFiled: September 2, 2021Date of Patent: June 13, 2023Assignee: Rigel Pharmaceuticals, Inc.Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
-
Patent number: 11667643Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: GrantFiled: June 25, 2021Date of Patent: June 6, 2023Assignee: Rigel Pharmaceuticals, Inc.Inventors: Somasekhar Bhamidipati, Simon Shaw, Ihab Darwish, Jiaxin Yu, Rao Kolluri, Vanessa Taylor, Esteban Masuda, Mark Irving
-
Publication number: 20230143161Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: ApplicationFiled: December 16, 2022Publication date: May 11, 2023Inventors: Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
-
Publication number: 20230123591Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.Type: ApplicationFiled: October 7, 2022Publication date: April 20, 2023Applicant: Rigel Pharmaceuticals, Inc.Inventors: Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
-
Publication number: 20230112865Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: ApplicationFiled: June 17, 2022Publication date: April 13, 2023Inventors: Yan CHEN, Jiaxin YU, Simon SHAW, Ihab DARWISH, Vanessa TAYLOR, Somasekhar BHAMIDIPATI, Zhushou LUO, Rao KOLLURI
-
Patent number: 11584758Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: GrantFiled: April 2, 2021Date of Patent: February 21, 2023Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ihab Darwish, Zhushou Luo, Vanessa Taylor
-
Patent number: 11578078Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: GrantFiled: November 6, 2020Date of Patent: February 14, 2023Assignee: Rigel Pharmaceuticals, Inc.Inventors: Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
-
Patent number: 11564930Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.Type: GrantFiled: September 4, 2020Date of Patent: January 31, 2023Assignee: Rigel Pharmaceuticals, Inc.Inventors: Jiaxin Yu, Ihab Darwish, Vanessa Taylor, Rao Kolluri, Yan Chen, Simon Shaw, Somasekhar Bhamidipati, Zhushou Luo
-
Publication number: 20230012676Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.Type: ApplicationFiled: September 2, 2021Publication date: January 19, 2023Applicant: Rigel Pharmaceuticals, Inc.Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
-
Patent number: 11466018Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.Type: GrantFiled: November 2, 2020Date of Patent: October 11, 2022Assignee: Rigel Pharmaceuticals, Inc.Inventors: Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
